The US Food and Drug Administration (FDA) has approved Fujirebio Diagnostics’ Alzheimer’s disease (AD) blood test to help ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s ...

(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...

The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...